Insights

Growing Financial Profile Despite recent bankruptcy filings, Mallinckrodt demonstrates a comeback with recent financing of almost $9.5 million, indicating potential liquidity and strategic repositioning opportunities for partners interested in their recovery phase.

Product Innovation Mallinckrodt has launched innovative medical products, including the self-injectable Acthar Gel for autoimmune conditions, which presents cross-selling opportunities in specialty pharmaceutical markets and expands their footprint in autoimmune therapies.

Regulatory and Patent Strength The company’s strong regulatory expertise and recent patent infringement win highlight robust intellectual property protections, making them a reliable partner for advanced biomedical collaborations and licensing opportunities.

Market Focus With a focus on autoimmune, rare diseases, neurology, and other specialized therapeutic areas, Mallinckrodt offers targeted partnership prospects in niche markets with high unmet needs and growth potential.

Strategic Asset Management Recent asset sales, such as the transfer of rights for certain products to external companies, suggest opportunities for collaboration on development, licensing, or acquisition of portfolio assets to expand market reach or enhance innovation pipelines.

Similar companies to IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.

IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. Tech Stack

IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. uses 8 technology products and services including SAS, SonarQube, Artifactory, and more. Explore IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s tech stack below.

  • SAS
    Business Intelligence
  • SonarQube
    Development
  • Artifactory
    Development
  • JD Edwards
    Enterprise
  • Veeva Vault
    Enterprise Content Management
  • SAP ERP Central Component (ECC)
    Enterprise Resource Planning
  • Video.js
    Javascript Libraries
  • Bootstrap
    UI Frameworks

Media & News

IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s Email Address Formats

IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. uses at least 3 format(s):
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. Email FormatsExamplePercentage
First.Last@mallinckrodt.comJohn.Doe@mallinckrodt.com
94%
FLast@mallinckrodt.comJDoe@mallinckrodt.com
2%
Last.First@mallinckrodt.comDoe.John@mallinckrodt.com
2%
FirstLast@mallinckrodt.comJohnDoe@mallinckrodt.com
2%
First.Last@mnk.comJohn.Doe@mnk.com
100%
First.Last@ikaria.comJohn.Doe@ikaria.com
89%
F.Last@ikaria.comJ.Doe@ikaria.com
6%
First@ikaria.comJohn@ikaria.com
3%
Last@ikaria.comDoe@ikaria.com
2%

Frequently Asked Questions

Where is IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s headquarters located?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s main headquarters is located at 53 Frontage Road po Box 9001 Third Floor Hampton, New Jersey United States. The company has employees across 5 continents, including North AmericaEuropeOceania.

What is IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s phone number?

Minus sign iconPlus sign icon
You can contact IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s official website and social media links?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s official website is mallinckrodt.com and has social profiles on LinkedIn.

How much revenue does IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. generate?

Minus sign iconPlus sign icon
As of April 2026, IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s annual revenue is estimated to be $5B.

What is IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s NAICS code?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. have currently?

Minus sign iconPlus sign icon
As of April 2026, IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. has approximately 91 employees across 5 continents, including North AmericaEuropeOceania. Key team members include Chief Executive Officer: A. T.Chief Executive Officer And Directeur General: D. T.Chief Executive Officer: L. C.. Explore IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s employee directory with LeadIQ.

What industry does IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. belong to?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. operates in the Pharmaceutical Manufacturing industry.

What technology does IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. use?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s tech stack includes SASSonarQubeArtifactoryJD EdwardsVeeva VaultSAP ERP Central Component (ECC)Video.jsBootstrap.

What is IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s email format?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s email format typically follows the pattern of First.Last@mallinckrodt.com. Find more IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. email formats with LeadIQ.

When was IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. founded?

Minus sign iconPlus sign icon
IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. was founded in 2007.

IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.

Pharmaceutical ManufacturingNew Jersey, United States51-200 Employees

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mission: Managing Complexity. Improving Lives.

Values: Quality, Integrity, Service

Principal Executive Office:
Mallinckrodt plc
Damastown Industrial Estate
Mulhuddart, Dublin 15
Ireland 

U.S. Headquarters:
675 McDonnell Blvd.
St. Louis, MO 63042
USA 

Website: www.mallinckrodt.com
Stock Ticker: MNK
Corporate Blog: http://blog.mallinckrodt.com/ 
Careers Website: www.mallinckrodt.com/careers 
Investor Relations: http://www.mallinckrodt.com/investors

Section iconCompany Overview

Headquarters
53 Frontage Road po Box 9001 Third Floor Hampton, New Jersey United States
Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2007
Employees
51-200

Section iconFunding & Financials

  • $50M$100M

    IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.'s revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.